We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA APPROVES GENERIC OXYCONTIN, BUT LAUNCH DELAYED BY LITIGATION
FDA APPROVES GENERIC OXYCONTIN, BUT LAUNCH DELAYED BY LITIGATION
March 24, 2004
Generic firms Endo Pharmaceuticals and Teva Pharmaceutical have received final FDA approval to market versions of Purdue Pharma’s powerful pain treatment OxyContin (oxycodone HCl), but ongoing patent litigation has put a hold on the product launches.